Chris Templin just wants to stay alive. He has Hemophilia B, a rare genetic blood clotting disease that can be fatal. He needs infusions three times a week, and the treatments are expensive. Templin estimates it’s costing an estimated $300,000 a month, or about $3.6 million a year, to keep him alive.
Templin has health insurance, but he is worried that PBMs – Pharmacy Benefits Managers – are conspiring to make his out-of-pocket costs so expensive, he won’t be able to afford his infusions. PBMs are intermediaries between healthcare companies and patients that were created to help save money by negotiating better prices with drug companies.
